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Among patients who survive to hospital admission after aneurysmal subarachnoid hemorrhage (SAH), clini-
cal deterioration caused by delayed cerebral ischemia (DCI) 
accounts for a major part of the morbidity and mortal-
ity.1,2 Current prevention and therapy of DCI are primarily 
based on a hypothesis of large-vessel vasospasm. Despite a 
marked reduction in the prevalence of vasospasm, intrave-
nous clazosentan neither reduced the incidence of DCI nor 
improved outcome in multicenter randomized controlled tri-
als.3 Furthermore, nimodipine, the only agent with a docu-
mented effect on the risk of DCI,4 does not reduce cerebral 
vasospasm and, thus, seems to exert its effect through differ-
ent mechanisms.5 Consequently, vasospasm should no longer 
be viewed as the single important mediator of DCI. Instead, 
alternative mechanisms leading to DCI should be explored.
MicroRNAs (miRNAs) are 22 nucleotides long, noncod-
ing RNA molecules involved in post-transcriptional regula-
tion of complementary mRNA targets.6 MiRNAs are highly 
tissue-specific. They act intracellularly but are transported outside 
the cells in exosomes and exist in stable forms in body fluids.7 
Specific miRNAs are involved in the development of neuronal 
apoptosis after experimental acute cerebral ischemia6,8,9 and are 
clinically associated with the severity of traumatic brain injury.10 
In the present explorative study, we compared miRNA profiles 
in cerebrospinal fluid (CSF) between neurologically healthy 
patients and SAH patients with and without subsequent develop-
ment of DCI. Moreover, we compared profiles obtained with 2 
different commonly used commercial high-throughput real-time 
quantification polymerase chain reaction (RT-qPCR) platforms. 
We hypothesized that the relative concentration of specific miR-
NAs would be altered between SAH and neurological healthy 
patients, as well as between SAH patients with and without DCI.
Materials and Methods
This was a prospective case–control study designed primarily to 
study miRNA in SAH and neurologically healthy patients. The 
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protocol was approved by the Danish Scientific Ethics Committee 
of the Capital Region (file No. H-3-2013-009), as well as the Danish 
Data Protection Agency (file No. RH-2013-30-0935), and registered 
on clinicaltrials.gov (file No. NCT01791257). According to Danish 
law, informed consent was obtained from either the patient or from 
their next of kin and general practitioner.
Enrollment
SAH Patients
From February 2013 to January 2014, patients admitted to the 
neurointensive care unit at Rigshospitalet, Copenhagen, with spon-
taneous aneurysmal SAH were screened for inclusion. Eligible 
participants were patients >18 years of age who had an external 
ventricular drain placed within 5 days after ictus. Exclusion criteria 
were the following: (1) inability of patient or next of kin to speak 
and understand Danish; (2) >24 hours’ uncertainty of the time of 
ictus; and (3) inability to diagnose DCI because of a persistent 
Glasgow Coma Score <7 as a result of initial brain injury, a known 
complication (eg, rebleeding, surgical/endovascular trauma), or 
deep sedation.
Neurologically Healthy Control Patients
From September to October 2013, all patients admitted to the ortho-
pedic department at Frederiksberg Hospital, Copenhagen, for elective 
lower limb surgery and planned for spinal anesthesia were screened 
for inclusion. Eligible participants had no clinically overt neurologi-
cal disease or diagnosis, were >18 years of age, and had an American 
Society of Anesthesiologists physical status classification ≤2.
Sampling of CSF
Using a strict protocol, including sterile precautions, CSF was sam-
pled from the external ventricular drain on day 5 after ictus in SAH 
patients and prior to administration of spinal anesthesia for orthope-
dic surgery in neurologically healthy patients. All CSF samples were 
put on ice immediately and spun within 15 minutes at 500g for 10 
minutes; the supernatant was stored at −80°C until use.
Primary Outcome Measures
All cases of SAH were diagnosed by computed tomography scan-
ning and computed tomographic angiography. Patients were con-
tinually evaluated for signs of DCI as described by Vergouwen et 
al.2 Because DCI is a clinical diagnosis based on the exclusion of 
other causes (eg, rebleeding, surgical complications, hydrocepha-
lus, and infection), confirmation or exclusion will be subjective 
in some cases.2 To minimize error, 2 physicians (S. Bache and R. 
Rasmussen) reviewed all clinical, biochemical, and radiological 
data, obtained 3 weeks from ictus, and independently assessed if 
cases of clinical deterioration fulfilled the criteria of DCI. Patients 
were categorized as definite DCI, probable DCI, possible DCI, 
probably not DCI, or definitely not DCI. Disagreements were dis-
cussed, and all decisions were made in consensus. Only patients 
with a priori agreement between the 2 physicians could be cate-
gorized as definitely DCI or definitely not DCI. According to the 
protocol, inclusion was stopped when at least 12 patients had been 
categorized as either definitely DCI or probably DCI and at least 12 
patients were categorized as either probably not DCI or definitely 
not DCI. Only patients categorized as definite DCI and definitely 
not DCI were compared in the final analysis.
Secondary Outcome Measures
To relate the CSF miRNA profiles to initial and secondary injury, as 
well as outcome, SAH patients were dichotomized according to the 
following:
• Clinical status on admission based on World Federation of 
Neurosurgical Societies grading scale (WFNS) with good 
grade (WFNS score 1–3) versus poor grade (WFNS score 4–5)
• Early brain injury (EBI) defined by our protocol according to 
the Glasgow Come Score at 24 hours after aneurysm closure as 
no or minor EBI (Glasgow Coma Score 13–15 and no major 
focal deficit) versus major EBI (Glasgow Coma Score 3–12 and 
major focal deficit)
• Presence or absence of angiographic vasospasm diagnosed by 
computed tomography or magnetic resonance angiographic se-
quences between 3 and 14 days from ictus
• Delayed cerebral infarction as defined by Vergouwen et al2
• Outcome at 3 months according to the modified Rankin Scale 
and classified as good (modified Rankin Scale score 0–2) ver-
sus poor (modified Rankin Scale score 3–6).
Spectrophotometric Measures of Hemolysis
Spectrophotometry was performed on each CSF sample; the net 
absorbance was calculated for hemoglobin and oxyhemoglobin 
using a standardized method11 and correlated against the non-
normalized average cycle quantification (Cq) value of all detected 
miRNAs.
MiRNA Profiling
CSF miRNA profiles were screened in individual patients using 1 
high-throughput RT-qPCR platform, which is based on the stem-
loop primer technique (TaqMan, Thermo Fisher, Cambridge, MA). 
Subsequently, the miRNAs that were detected in all SAH patients 
were validated using another high-throughput RT-qPCR platform, 
which is based on the locked nuclear acid technique (LNA, Exiqon, 
Vedbaek, Denmark).
Screening: RNA Isolation
Total RNA was isolated from 200 μL of each sample of CSF accord-
ing to the manufacturer’s protocol (Total RNA isolation kit, Appendix 
B; Norgen Biotek, Thorold, Canada). As proposed by the manufac-
turer, β-mercaptoethanol was added to the lysis solution.
Screening: Real-Time Quantification
We screened for a total of 754 miRNAs. Reverse transcription and 
RT-qPCR was performed as previously described.12 Briefly, for 
each sample, a fixed volume of 6 μL eluted RNA sample was mixed 
on ice with 9 μL of a reverse transcription reaction containing 1.6 
μL of 10× RT buffer, 1.8 μL of MgCl2, 0.2 μL of RNase-inhibitor (20 U/μL), 0.4 μL of dNTPs with dTTP (100 mmol/L), 3.0 μL of 
Multiscribe Reverse Transcriptase (50 U/μL), 1.6 μL of Megaplex 
RT primers (×10), and 0.4 μL of nuclease free water. Reverse tran-
scription was performed using 40 cycles of 16°C, 2 minutes; 42°C, 
1 minute; and 50°C, 1 s followed by 85°C for 5 minutes and hold at 
4°C. For each sample, a preamplification reaction comprising 62.5 
μL of TaqMan PreAmp Master Mix (2×), 12.5 μL of Megaplex 
PreAmp Primers (10×), 37.5 μL of nuclease-free water, and 12.5 
μL of RT product were mixed on ice. After 10 minutes at 95°C, 2 
minutes at 55°C, and 2 minutes at 72°C, the cDNA was subjected 
to 12 cycles of 15 s at 95°C and 4 minutes at 60°C followed by 
10 minutes at 99.9°C and hold at 4°C. The preamplified product 
was diluted with 375 μL of 0.1 TE buffer. Subsequently, 450 μL 
of diluted preamplified product was mixed on ice with 450 μL 
of TaqMan Fast Advanced Master Mix and 800 μL loaded on a 
TaqMan Human MicroRNA Array Card. RT-qPCR was performed 
using a Viia 7 real-time PCR system (Applied Biosystems, Foster 
City, CA). The above steps were performed using Human Pools A 
v.2.1 and repeated using Human Pools B v.3.0 for a total screen of 
754 specific miRNAs. Reagents and array cards were all purchased 
from Invitrogen, Carlsbad, CA.
Validation: RNA Isolation
Total RNA was isolated from 200 μL of each sample of CSF using 
miRCURY RNA Isolation Kit Biofluids. This included the addition 
of MS2 carrier RNA (Roche, Switzerland) and spike-ins, UniSp2, 
UniSp4, and UniSp5, according to the manufacturer’s protocol 
(Exiqon, Vedbæk, Denmark).
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Validation: Real-Time Quantification
The validation was tested for the presence of 151 miRNAs of the 
155 miRNAs originally detected in all SAH patients during screen-
ing analysis because 4 of the original targets were excluded either 
because they represent mRNA or tRNA fragments rather than 
miRNA or because they were unavailable from the manufacturer. 
Reverse transcription was performed using the Universal cDNA 
synthesis kit II and included the addition of spike-ins, UniSp6, 
and cel-miR-39, according to the manufacturer’s protocol (Exiqon, 
Vedbæk, Denmark). Based on our own optimization studies, we used 
9.6 μL of template RNA for a total volume of 24 μL. After incuba-
tion, cDNA was diluted 100× in nuclease-free water and ExiLENT 
SYBR Green master mix according to the manufacturers protocol 
(Exiqon, Vedbæk, Denmark) with addition of a ROX reference dye 
50× (Invitrogen, Carlsbad, CA). Pick & Mix microRNA PCR panels 
(Exiqon, Vedbæk, Denmark) were loaded with 10 μL in each of 384 
wells, and RT-qPCR was performed using a Viia 7 real-time PCR sys-
tem (Applied Biosystems, Foster City, CA), with settings suggested 
by the manufacturer including a melting curve analysis (Exiqon).
Sample Size Calculations
Using a web-based sample size calculator for microarray studies13 
and an SD of 0.5 Cq values based on in-house RT-qPCR measure-
ments of biological replicates of CSF, we estimated that 8 patients in 
each group would be necessary to detect a 2-fold change. To allow 
for dropouts, exclusion of patients difficult to categorize as DCI, and 
missing data in RT-qPCR profiling, we planned to include 12 patients 
in each of the 3 groups (ie, SAH with and without DCI, as well as 
neurologically healthy patients).
Preprocessing and Quality Control
For all targets, the RT-qPCR data were preprocessed by setting cycle 
threshold to 0.1 for screening and 0.01 for validation; the baseline 
was set from 3 to 15 for screening and calculated automatically by 
the instrument software for validation. Screened miRNA profiles with 
U6snRNA replicate SDs >0.5 Cq values were excluded from further 
analysis. Validated miRNA profiles were subjected to interplate 
calibration using the synthetic DNA spike-in, UniSp3, and internal 
amplification control using the synthetic RNA spike-ins UniSp2, 
-4, and -6 and cel-miR-39-3p in GenEx v.6.0.1 (Multid, Göteborg, 
Sweden). MiRNA targets with Cq values >32 in the screening study 
and 36 in the validation study were discarded.
Normalization and Statistical Analysis
The average Cq value of all detected miRNAs in each sample dif-
fered between SAH and neurologically healthy patients. Thus, non-
normalized data were used to compare these groups. Otherwise, Cq 
values were normalized to the sample mean.14 GenEx v.6.0.1 (Multid, 
Göteborg, Sweden) was used for preprocessing, and fold changes 
were calculated using the formula 2(−ΔΔCq). Statistical analyses were 
performed using Qlucore Omics Explorer 3.2. Continuous variables 
were tested for normality, and groups were compared using Student’s 
t test. One-way hierarchically clustered heat maps were generated 
using Euclidean distance and average linkage. Significance criteria 
were defined as P<0.001 for non-normalized data and P<0.05 for 
normalized data. As an estimate of the false discovery rate, corre-
sponding q values were calculated using the Benjamini & Hochberg 
procedure where applicable.15 In this context, a q value of 0.05 equals 
one false-positive discovery in 20 significant discoveries, and lower q 
values equal lower risk of a false-positive discovery.
Results
Patients
During 11 months, 54 adult SAH patients treated with exter-
nal ventricular drainage were screened for participation in 
the study. Thirty-six patients were included, of whom 7 were 
later excluded. The remaining 29 patients were grouped as 
follows: definitely DCI (N=8), probably DCI (N=5), possible 
DCI (N=3), probably not DCI (N=4), and definitely not DCI 
(N=9). The miRNA profiles for 2 patients failed quality con-
trol after RT-qPCR, leaving miRNA profiles from a total of 27 
SAH patients for final analyses.
During October and November 2013, 14 neurologically 
healthy control patients were included; 2 were subsequently 
excluded as CSF could not be sampled. Two miRNA profiles 
failed quality control, leaving 10 miRNA profiles for final 
analyses.
Please see Figure 1 and Table 1 for details on patient recruit-
ment and clinical characteristics.
Screening and Validation miRNA Analyses
Detection rates of miRNAs for each samples are presented 
in Table 2. Both the screening and validation study detected 
an increased number of miRNAs in CSF from SAH patients 
compared with neurologically healthy patients. Also the aver-
age Cq value for all miRNAs in each sample was higher in 
SAH patients (data not shown). Standard deviations of the Cq 
values for each miRNA within samples were similar between 
the 2 techniques and increased as expected when Cq values 
increased consistent with lower copy numbers. Conversely, 
raw and normalized Cq values of the 66 miRNAs detected 
with both techniques in all SAH patients correlated well 
Figure 1. Flow diagram of patient inclusion. CSF indicates cere-
brospinal fluid; DCI, delayed cerebral ischemia; GCS, Glasgow 
Coma Scale; RT-qPCR, real-time quantification polymerase 
chain reaction; and SAH, subarachnoid hemorrhage. *GCS <7 
(2 because of poor neurological performance, 1 needed heavy 
sedation for cardiopulmonary complication, and 1 had a throm-
bus of a posterior inferior cerebellar artery at day 3).
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between screening and validation. For raw and normalized 
Cq values for all miRNAs in all samples for both studies, see 
related data in the online-only Data Supplement: .
Correlation of miRNA to Hemolysis
In profiling studies of circulating miRNA, quantification of 
miR-16-5p and -451a have been recommended to evaluate 
serum and plasma samples for hemolysis.16 In agreement with 
this, we found that Cq values of miR-16-5p and -451a, as well 
as the average Cq value for all miRNAs in each sample, corre-
lated well to the net absorbance of oxyhemoglobin and hemo-
globin in the CSF of SAH patients (Figure I and Table I in the 
online-only Data Supplement).
SAH Versus Healthy
Of the 151 miRNAs that were detected in the screening study 
and targeted during validation, 66 exhibited an increase in 
SAH compared with neurologically healthy patients, both in 
the screening (P<0.001 and q<0.002) and validation study 
(P<0.001 and q<0.0009); and none exhibited a decrease. 
Figure 2 shows the distribution of the 66 increased miRNAs 
for each patient in each study. Fold change, as well as P and q 
values are presented for each of these miRNAs in Table II in 
the online-only Data Supplement.
Occurrence of DCI
In the screening, a relative increase in miR-10b-3p, 21-5p, 
-132-3p, -146a-5p, 193a-5p, and -221-3p and a relative 
decrease in miR-208a-3p, -490-3p, -520h and -553 and -643 
was found in CSF from SAH patients with DCI, compared 
with those without DCI (P<0.05 and q=0.74). Validation con-
firmed a relative increase in 2 of these, namely, miR-21-5p 
and -221-3p in patients with DCI compared with SAH patients 
without DCI (P<0.05 and q=0.38). Still, as can be deducted 
from the q values, none of these remained significant after 
correction for multiple testing. For the remaining miRNAs, 
none showed significant change in both the screening and the 
validation study. Figure 3 shows fold change and sample by 
sample correlations between screening and validation analy-
ses for miR-21-5p and -221-3p.
Secondary End Points
For the secondary end points, only results for miRNAs that 
differed in both screening and validation are given. We found 
a relative increase in miR-486-5p in patients with a poor neu-
rological admission status (WFNS score 4–5) compared with 
those with a good status (WFNS score 1–3). Angiographic 
vasospasm was associated with a relative increase in miR-
132-3p, -19b-3p, -210-3p, -221-3p, and -484. MiR-221-3p, 
which was also associated with DCI, showed a 3.3-fold 
increase in the screening study and a 2.6-fold increase in the 
validation study in SAH patients with angiographic vaso-
spasm compared with patients without. These associations 
were strengthened by the fact that miR-221-3p was even lower 
in the neurologically healthy patients. No miRNAs differed 
between SAH patients with and without delayed cerebral 













66±9* 57±13* 56±11† 59±16†
Sex
  Men 7 8 2 1
  Women 3 19 6 8
WFNS grade
  1  3 1 2
  2  5 2 2
  3     
  4  11 5 2
  5  8  3
Aneurysm location
  Anterior  11 4 2
  Internal  5 1 3
  Media  7 2 2
  Posterior  4 1 2
Aneurysm repair
  Coil  16‡ 6‡ 6
  Clip  12‡ 3‡ 3
Fisher grade
  1     
  2  1  1
  3  21 7 7
  4  5 1 1
DCI indicates delayed cerebral ischemia; SAH, subarachnoid hemorrhage; 




‡One patient underwent both clipping and coiling.



























miRNA detected in 
all patients
19 60
miRNA indicates microRNAs; and SAH, subarachnoid hemorrhage.
*Only miRNAs present in >60% of samples were used for final analysis. 
This threshold was selected because it led to at least 16 SAH patients having 
the given miRNA detected, which was in accordance with our sample size 
calculation.
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infarction in both the screening and the validation. Finally, we 
observed a relative increase of miR-9-3p both in patients with 
major signs of EBI after aneurysm repair and in patients with 
a poor outcome 3 months after SAH, compared with patients 
without these injuries. Figure 4 shows fold change and sample 
by sample correlations between screening and validation anal-
yses for secondary end points.
Discussion
According to our results, considerable changes occur in the 
miRNA composition of CSF after SAH, indicating a highly 
altered intrathecal miRNA environment at this time. On aver-
age, 48 additional miRNAs were present in CSF from SAH 
patients, and the 66 most differentially expressed miRNAs 
changed by a median of 34-fold (median P=1×10–8).
Experimental manipulation of levels of intrathecal miRNA 
with mimics or inhibitors has shown regulation of central 
pathways of apoptosis and neuronal survival after acute cere-
bral ischemia.17–19 Although inhibitory in nature, both up- and 
downregulated miRNAs could be of relevance depending on 
whether they target mRNA related to proapoptotic8 or anti-
apoptotic pathways.9 Extensive research into the origin of 
angiographic vasospasm and DCI has proposed that activation 
of various pathways are essential for their development.5,20 
Our study is the first that aims to associate cerebral changes in 
miRNA with DCI, as well as with outcome after SAH.
Figure 2. One-way hierachically clustered relative differences of non-normalized Cq values of microRNAs, which differ in cerebrospinal 
fluid between subarachnoid hemorrhage (SAH; red) and neurologically healthy patients (green) in both the screening (P<0.001, q<0.002) 
and the validation study (P<0.001, q<0.0009). Downregulation shown in green and upregulation in red. The line “Hemolysis” indicates the 
degree of hemolysis as measured by the net absorbance of oxyhemoglobin and colored from red (high) to yellow (low); the white color 
represents a value that is either out of range on the spectrophotometer (SAH) or not available (Healthy).
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We found a relative increase of miR-21-5p and miR-221-3p 
5 days after ictus in CSF from patients who developed DCI 
and of miR-221-3p in those with angiographic vasospasm. 
Experimentally, miR-21 has been studied extensively in many 
organs.6,21 In the context of the present study, miR-21 was 
increased after neointimal lesion of the carotid artery in rats. 
In the same study, inhibition of miR-21 reduced neointima 
formation, decreased proliferation, and increased apoptosis 
Figure 3. MicroRNAs (miRNAs) associated with delayed cerebral ischemia (DCI) in both screening and validation studies. Table (left) 
shows fold changes, significance levels (P value), and estimated false discovery rates (q value) for each miRNA in each study. Heat maps 
(right) depict sample by sample correlation between screening and validation of relative increases (red) or decreases (green) in each spe-
cific miRNA.
Figure 4. MicroRNAs (miRNAs) associated with neurological condition on admission (WFNS), early brain injury (EBI), angiographic vaso-
spasm (Spasm), and outcome after 3 months (mRS) in both screening and validation studies. Tables (left) show fold changes, significance 
levels (P value), and estimated false discovery rates (q value) for each miRNA in each study. Heat maps (right) depict sample by sample 
correlation between screening and validation of relative increases (red) or decreases (green) in each specific miRNA. mRS indicates modi-
fied Rankin Scale; and WFNS, World Federation of Neurosurgical Societies SAH grading scale.
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of cells related to the injured vessel walls,22 indicating that 
miR-21 promoted reparatory mechanisms in this model. In 
contrast, another experimental study after middle cerebral 
artery occlusion showed reduced infarction after intrathecal 
inhibition of miR-24 but not miR-21.17 Recently, Stylli et al23 
studied miRNA profiles in CSF from 19 SAH patients and 4 
healthy patients. As in the present study, the most pronounced 
miRNA differences were found between SAH and control 
patients, but neither miR-21-5p nor miR-221-3p differed sig-
nificantly between the reported groups.23 However, method-
ological differences, such as a variation of time from ictus to 
CSF sampling, the choice of instrument for miRNA detec-
tion, and a primary focus on angiographic vasospasm, make 
direct comparisons difficult between the study by Stylli et al23 
and our findings. Recently, 2 other groups have studied circu-
lating miRNAs after SAH. One study reported that a combi-
nation of plasma levels of miR-1290, -4463, -4532, and -4793 
on day 7 could differentiate between SAH patients with and 
without delayed cerebral infarction.24 The other study found 
the serum levels of miR-502-5p and -1297 to be upregulated 
72 hours after SAH in patients with a poor compared with 
a good outcome, as well as in SAH patients compared with 
healthy volunteers.25 However, none of the miRNAs reported 
in these studies differed significantly between groups in the 
present study. To our knowledge, hitherto no study has com-
pared intrathecal and circulating miRNA profiles in SAH, 
but it would be interesting to see if an increase in circulating 
brain-specific miRNA could be associated with brain injury, 
as previously proposed for S100B and neuron specific eno-
lase.26,27 In another clinical study of acute ischemic stroke, 
increased miR-221 was also reported in CSF28; the same 2 
miRNAs, miR-21-5p and miR-221-3p, have been proposed 
as circulating biomarkers in ischemic stroke patients.29
We also found a >6-fold relative increase of miR-9-3p in 
patients with EBI or a poor outcome after 3 months, or both. 
Although the significance of this miRNA in the pathophysiol-
ogy of SAH needs to be further established, the finding does 
suggest that future dynamic studies of CSF miRNAs in the 
early phase may help to reveal the extent of brain injury and, 
thereby, aid prognostication.
A strength of this study is the use of 2 different miRNA pro-
filing platforms. Despite rapid development of new miRNA 
detection systems, RT-qPCR remains the gold standard for 
reliable detection of extracellular miRNA. As considerable 
analytic variability has been demonstrated between RT-qPCR 
platforms,30 we elected to conduct the screening part with the 
widely used and probably most sensitive30 stem-loop primer 
technique. This was followed up by validation using the 
more specific30 locked nuclear acid technique. The validation 
method includes melting curve analyses and extensive use of 
spike-ins integrating quality control after RNA extraction, 
reverse transcription, and RT-qPCR. The results indicate that 
the previously reported differences between RT-qPCR tech-
niques30 also apply to studies of CSF and stresses the need 
for caution when interpreting results from either technique in 
isolation. Even so, the fact that we are able to measure this 
large number of miRNAs reliably in CSF with a low analytic 
variation may hold some promise to explore miRNAs in the 
pathophysiology of other types of acute brain injury.
For each CSF sample, the net absorbance of oxyhemo-
globin correlated well to the mean Cq values for each sam-
ple. Therefore, comparisons between subgroups of SAH 
patients, where the mean normalization approach was used, 
provide Cq values relative to the mean Cq value for each 
miRNA in each sample. This strategy partly compensates 
for the contamination of CSF with blood. Consequently, a 
miRNA that is found to be relatively downregulated between 
groups may well exhibit an unchanged or increased absolute 
concentration.
The present findings apply only to SAH patients requir-
ing external ventricular drainage. However, one could spec-
ulate that SAH patients without this need are more likely to 
have a miRNA profile resembling those SAH patients in our 
study with less severe blood contamination and hemolysis 
in the CSF. Furthermore, the association of mir-21-5p and 
-221-3p to DCI was not significant when corrected for mul-
tiple comparisons. Nevertheless, in our opinion, the repro-
ducibility when using another RT-qPCR technique justifies 
reporting these associations, although their use should be 
restricted to hypothesis generation. Also, the strict criteria 
for DCI, with the exclusion of any patient who was difficult 
to categorize, increases the likelihood that a true association 
reflect processes related to DCI and not for instance poor 
neurological status on admission or EBI. Further, miRNA 
profiles in CSF were screened at a fixed time, 5 days after 
ictus. In contrast, DCI occurred variably during Day 4 to 
14, and it could be argued that any changes in miRNA asso-
ciated with DCI are more likely to occur at a specific point 
up until or after the occurrence of DCI and not in relation to 
ictus. Additionally, although we excluded patients in whom 
time of ictus could not be estimated with an error margin of 
<24 hours, we cannot exclude that a preceding minor hem-
orrhage or errors at estimating the time of ictus might have 
skewed the average miRNA profile because CSF was not 
truly sampled at 5 days after ictus. Finally, the neurologi-
cally healthy patients differed slightly from SAH patients 
regarding age and sex. Nonetheless, age and sex did not 
drive any of the reported large differences between SAH 
and neurologically healthy patients (data not shown). Also, 
we cannot exclude that the neurologically healthy patients 
had a nondiagnosed neurological disease. To interpret these 
results, one also needs to consider that the diagnosis of DCI 
is to a large extent based on clinical signs and exclusion of 
other diagnoses. Therefore, DCI may well constitute the 
final common pathway of many activated or deactivated 
physiological or pathophysiological pathways. Moreover, 
the present study is one of association only and does not 
imply causality.
We have previously reported that certain miRNAs may be 
detected in cerebral microdialysate,12
 although quantifica-
tion was performed solely with the highly sensitive protocol 
reserved for screening in the present study. Regarding our 
present finding of marked changes in the intrathecal miRNA 
profile after SAH, its pathophysiological implications are to 
date unknown. With our current understanding of the role of 
miRNAs, extracellular miRNA levels are important only inas-
much as they reflect the intracellular levels. In vitro studies 
indicate that an energy-dependent equilibrium exists between 
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intracellular and extracellular miRNA concentrations,31 that 
is, the extracellular levels may reflect intracellular levels. 
However, potential additional mechanisms, such as cell lysis, 
and the kinetics of these mechanisms await further studies.
Summary
In patients with SAH, the miRNA profile in CSF differs mark-
edly from that in normal CSF. Intrathecal changes in miRNA 
could be associated to the development of DCI.
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Supplemental Figure I - Hemolysis and miRNA correlation. One way hierarchically clustered relative differences of non normalized Cq values of the 
13 miRNA most correlated (p < 0.0001, linear regression) to net oxyhemoglobin absorbance (NOA) in cerebrospinal fluid from SAH patients in both 
the screening and the validation study. Downregulation shown in green, upregulation in red (left color legend). High net absorbance shown in red, low 
in white.
Hgb, net absorbance of hemoglobin; Average, average quantification value of all miRNA targets for each sample.
Screening Validation
SUPPLEMENTAL MATERIAL
P-values of the 13 miRNA most correlated (linear 
regression) to net oxyhemoglobin absorbance (NOA) 
in cerebrospinal fluid from SAH patients in both the 
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Fold	change p-value q-value Fold	change p-value q-value
hsa-let-7b-5p 105,5 2,23E-08 3,88E-08 42,0 4,65E-09 9,59E-09
hsa-miR-106a-5p 56,1 1,08E-09 3,95E-09 153,5 6,91E-12 9,12E-11
hsa-miR-125b-5p 12,3 5,81E-06 6,50E-06 23,4 9,47E-08 1,56E-07
hsa-miR-126-3p 96,4 1,51E-08 2,84E-08 119,1 2,69E-12 4,44E-11
hsa-miR-1274B 103,1 2,65E-08 4,37E-08 19,2 5,20E-06 6,60E-06
hsa-miR-130a-3p 18,8 2,67E-07 3,52E-07 9,9 1,09E-05 1,27E-05
hsa-miR-130b-3p 87,5 2,43E-11 1,46E-10 4,8 6,82E-05 7,26E-05
hsa-miR-132-3p 605,9 1,45E-15 3,18E-14 98,6 1,21E-11 9,77E-11
hsa-miR-140-5p 70,1 5,67E-08 8,70E-08 11,9 2,06E-05 2,30E-05
hsa-miR-142-3p 218,7 3,09E-12 4,07E-11 61,6 4,46E-10 1,40E-09
hsa-miR-146a-5p 28,7 1,04E-10 5,73E-10 19,3 1,25E-07 1,96E-07
hsa-miR-150-5p 10,4 3,38E-09 8,09E-09 32,4 5,67E-10 1,70E-09
hsa-miR-152-3p 9,2 1,22E-06 1,49E-06 12,6 6,78E-06 8,29E-06
hsa-miR-15a-5p 36,1 1,05E-07 1,50E-07 61,4 1,99E-09 4,88E-09
hsa-miR-15b-5p 818,6 5,18E-14 8,54E-13 53,0 1,53E-09 4,04E-09
hsa-miR-16-5p 318,5 2,71E-10 1,23E-09 320,6 2,66E-12 4,44E-11
hsa-miR-17-5p 67,1 1,65E-09 4,53E-09 3,8 7,59E-04 7,59E-04
hsa-miR-185-5p 63,7 2,95E-09 7,48E-09 150,8 8,34E-12 9,17E-11
hsa-miR-186-5p 31,9 1,61E-09 4,53E-09 10,2 9,42E-06 1,13E-05
hsa-miR-191-5p 18,0 2,61E-08 4,37E-08 20,6 5,65E-07 7,76E-07
hsa-miR-192-5p 3,8 2,93E-05 2,97E-05 18,7 3,27E-07 4,59E-07
hsa-miR-197-3p 173,6 6,22E-12 5,25E-11 23,5 7,88E-09 1,58E-08
hsa-miR-19a-3p 119,2 5,27E-07 6,56E-07 139,5 6,32E-11 2,98E-10
hsa-miR-19b-3p 52,0 4,89E-10 2,02E-09 165,6 1,49E-11 9,77E-11
hsa-miR-204-5p 7,0 1,37E-09 4,10E-09 10,8 1,04E-07 1,67E-07
hsa-miR-20a-5p 17,1 1,97E-08 3,61E-08 134,5 1,49E-10 5,79E-10
hsa-miR-21-5p 247,5 1,25E-15 3,18E-14 76,7 1,77E-13 8,69E-12
hsa-miR-210-3p 312,0 1,50E-11 9,89E-11 39,0 3,47E-09 7,64E-09
hsa-miR-221-3p 970,0 1,09E-16 7,21E-15 13,8 2,53E-08 4,52E-08
hsa-miR-222-3p 6,0 1,25E-08 2,50E-08 78,6 2,63E-13 8,69E-12
hsa-miR-223-3p 55,3 8,16E-12 5,99E-11 264,9 1,35E-09 3,88E-09
hsa-miR-223-5p 161,8 2,47E-09 6,53E-09 9,6 8,90E-05 9,18E-05
hsa-miR-24-3p 18,5 6,21E-08 9,31E-08 54,1 1,54E-08 2,90E-08
hsa-miR-25-3p 22,3 8,13E-09 1,68E-08 164,1 1,69E-11 9,77E-11
hsa-miR-26a-5p 14,6 2,77E-05 2,90E-05 12,8 2,83E-07 4,06E-07
hsa-miR-26b-5p 38,8 3,43E-09 8,09E-09 15,5 8,70E-07 1,17E-06
hsa-miR-27a-3p 60,5 1,34E-09 4,10E-09 68,2 9,29E-11 4,09E-10
hsa-miR-28-3p 121,8 5,90E-10 2,29E-09 14,1 2,17E-06 2,86E-06
hsa-miR-29a-3p 38,3 4,04E-07 5,22E-07 24,2 3,06E-08 5,31E-08
hsa-miR-29c-3p 4,8 6,09E-06 6,59E-06 23,2 1,83E-07 2,82E-07
hsa-miR-30a-5p 3,3 1,41E-05 1,50E-05 14,3 2,15E-07 3,15E-07






Fold	change p-value q-value Fold	change p-value q-value
hsa-miR-30c-5p 5,3 1,53E-07 2,10E-07 18,6 1,46E-09 4,01E-09
hsa-miR-30d-5p 3,6 2,82E-05 2,91E-05 67,4 1,78E-11 9,77E-11
hsa-miR-320a 30,7 1,25E-09 4,10E-09 28,8 2,74E-09 6,44E-09
hsa-miR-324-3p 64,9 2,06E-08 3,67E-08 22,5 2,09E-08 3,83E-08
hsa-miR-324-5p 52,7 1,31E-09 4,10E-09 10,3 3,44E-05 3,72E-05
hsa-miR-331-3p 13,0 5,92E-06 6,51E-06 7,2 8,77E-05 9,18E-05
hsa-miR-335-5p 38,3 7,96E-08 1,17E-07 14,0 1,89E-07 2,84E-07
hsa-miR-342-3p 74,4 4,76E-07 6,05E-07 17,4 6,66E-06 8,29E-06
hsa-miR-34b-3p 7,9 4,97E-06 5,65E-06 6,2 1,13E-05 1,29E-05
hsa-miR-34c-5p 20,9 7,66E-09 1,63E-08 10,4 2,73E-05 3,01E-05
hsa-miR-361-5p 39,9 2,46E-07 3,32E-07 23,2 1,44E-08 2,79E-08
hsa-miR-423-5p 58,7 5,50E-09 1,25E-08 19,2 8,35E-08 1,41E-07
hsa-miR-451a 277,5 6,97E-09 1,53E-08 268,1 4,25E-10 1,40E-09
hsa-miR-484 70,1 2,79E-10 1,23E-09 42,4 3,15E-10 1,15E-09
hsa-miR-486-5p 129,0 3,54E-08 5,69E-08 93,6 2,83E-09 6,44E-09
hsa-miR-532-3p 64,7 1,39E-07 1,95E-07 32,9 1,69E-11 9,77E-11
hsa-miR-532-5p 344,1 5,06E-12 5,25E-11 22,5 3,98E-09 8,48E-09
hsa-miR-574-3p 15,6 6,10E-04 6,10E-04 12,3 2,77E-06 3,58E-06
hsa-miR-590-5p 6,5 2,66E-06 3,08E-06 49,3 4,01E-10 1,39E-09
hsa-miR-660-5p 183,4 6,37E-12 5,25E-11 35,5 1,32E-10 5,46E-10
hsa-miR-92a-3p 7,0 4,42E-08 6,94E-08 113,2 1,31E-11 9,77E-11
hsa-miR-93-3p 73,9 1,28E-06 1,53E-06 5,9 6,39E-04 6,48E-04
hsa-miR-93-5p 323,1 2,24E-10 1,14E-09 109,1 3,39E-11 1,72E-10
hsa-miR-99b-5p 18,1 1,59E-06 1,87E-06 9,9 1,09E-05 1,27E-05
MiRNA	target Screening	study Validation	study
